CD158k/KIR3DL2 Is a New Phenotypic Marker of Sezary Cells: Relevance for the Diagnosis and Follow-Up of Sezary Syndrome

CD158k molecules belong to the family of killer cell immunoglobulin-like receptors (KIR) that are expressed on a minor population of circulating NK and CD8+ T lymphocytes. Here, we report a strong positive correlation between the percentage of CD158k+ blood lymphocytes analyzed by flow cytometry and...

Full description

Saved in:
Bibliographic Details
Published in:Journal of investigative dermatology 2004-03, Vol.122 (3), p.820-823
Main Authors: Poszepczynska-Guigné, Ewa, Schiavon, Valérie, D'Incan, Michel, Echchakir, Hamid, Musette, Philippe, Ortonne, Nicolas, Boumsell, Laurence, Moretta, Alessandro, Bensussan, Armand, Bagot, Martine
Format: Article
Language:English
Subjects:
Biological and medical sciences
Biomarkers, Tumor - blood
CD158k
cutaneous lymphoma
Dermatology
Flow Cytometry
Follow-Up Studies
Hematologic and hematopoietic diseases
Humans
KIR3DL2
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphocytes - chemistry
Medical sciences
Phenotype
Receptors, Antigen, T-Cell, alpha-beta - analysis
Receptors, Immunologic - blood
Receptors, KIR
Receptors, KIR2DL2
Receptors, KIR3DL2
Sezary cells
Sezary syndrome
Sezary Syndrome - diagnosis
Skin Neoplasms - diagnosis
tumor marker
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CD158k molecules belong to the family of killer cell immunoglobulin-like receptors (KIR) that are expressed on a minor population of circulating NK and CD8+ T lymphocytes. Here, we report a strong positive correlation between the percentage of CD158k+ blood lymphocytes analyzed by flow cytometry and the percentage of atypical circulating cells (Sezary cells) determined by cytomorphology in a large group of patients with Sezary syndrome. Moreover, we show that circulating CD4+CD158k+ lymphocytes correspond to the malignant clonal cell population. Our findings suggest that the CD158k marker could be a useful tool for the evaluation of the circulating tumoral burden and the follow-up of patients with Sezary syndrome.
ISSN:0022-202X
1523-1747
DOI:10.1111/j.0022-202X.2004.22326.x